Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed May 15, 2025 · 10-Q · 45 days after period end · 0001641172-25-010798
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$54.07M | -$526.70K | -$809.81K | -$462.69K |
| EPS Diluted | -$12.50 | -$545.79 | -$0.42 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end
